Your browser is no longer supported. Please, upgrade your browser.
BCDA BioCardia, Inc. monthly Stock Chart
BioCardia, Inc.
Index- P/E- EPS (ttm)-1.96 Insider Own11.60% Shs Outstand12.62M Perf Week5.86%
Market Cap27.02M Forward P/E- EPS next Y-0.96 Insider Trans46.77% Shs Float7.35M Perf Month15.20%
Income-15.50M PEG- EPS next Q-0.29 Inst Own9.80% Short Float0.39% Perf Quarter0.43%
Sales0.30M P/S90.08 EPS this Y20.60% Inst Trans-8.45% Short Ratio0.38 Perf Half Y-42.26%
Book/sh0.33 P/B7.12 EPS next Y38.90% ROA-178.90% Target Price- Perf Year-38.96%
Cash/sh0.64 P/C3.65 EPS next 5Y- ROE-496.90% 52W Range1.91 - 6.75 Perf YTD-36.14%
Dividend- P/FCF- EPS past 5Y- ROI-613.90% 52W High-65.19% Beta1.82
Dividend %- Quick Ratio- Sales past 5Y10.70% Gross Margin86.90% 52W Low23.04% ATR0.12
Employees20 Current Ratio2.00 Sales Q/Q-82.50% Oper. Margin- RSI (14)59.52 Volatility6.36% 5.58%
OptionableNo Debt/Eq0.12 EPS Q/Q51.50% Profit Margin- Rel Volume0.39 Prev Close2.37
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume74.07K Price2.35
Recom2.00 SMA2010.67% SMA504.94% SMA200-20.74% Volume28,726 Change-0.84%
Nov-10-20 07:00AM  
Oct-26-20 07:30AM  
Oct-20-20 07:05AM  
Sep-29-20 08:00AM  
Aug-31-20 06:12PM  
Aug-26-20 07:00AM  
Aug-13-20 07:00AM  
Aug-12-20 12:30PM  
Aug-07-20 08:00AM  
Aug-05-20 11:15AM  
Jul-22-20 06:51AM  
Jul-01-20 10:20AM  
Jun-29-20 08:00AM  
Jun-17-20 08:30AM  
May-15-20 08:00AM  
May-05-20 07:00AM  
Apr-30-20 08:00AM  
Apr-28-20 03:08PM  
Apr-14-20 08:00AM  
Apr-09-20 02:03PM  
Apr-02-20 08:00AM  
Mar-31-20 08:00AM  
Mar-29-20 08:58AM  
Mar-12-20 08:00AM  
Feb-13-20 06:30AM  
Jan-14-20 08:00AM  
Jan-08-20 08:00AM  
Dec-30-19 10:40AM  
Nov-19-19 05:24PM  
Nov-11-19 07:44AM  
Oct-28-19 08:00AM  
Oct-08-19 08:00AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-16-19 08:00AM  
Aug-21-19 08:00AM  
Aug-08-19 08:30AM  
Aug-06-19 04:05PM  
Aug-02-19 09:45AM  
Jul-25-19 06:00AM  
Jun-12-19 08:00AM  
Jun-06-19 08:00AM  
May-23-19 03:23PM  
May-20-19 08:00AM  
May-08-19 08:00AM  
Apr-02-19 08:00AM  
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Altman PeterPresident and CEONov 13Buy2.095001,046206,400Nov 13 06:33 PM
Altman PeterPresident and CEONov 12Buy2.072,0004,130205,900Nov 13 06:33 PM
Altman PeterPresident and CEONov 10Buy1.982,5004,950203,900Nov 12 06:15 AM
Duckers EricChief Medical OfficerNov 02Sale2.018,43516,95412,088Nov 03 06:06 PM
Allen Jim L.DirectorJun 19Buy2.10142,850299,985668,200Jun 23 09:22 PM
STERTZER SIMON HDirectorJun 19Buy2.10142,850299,985187,983Jun 23 09:21 PM
Blank Andrew ScottDirectorJun 19Buy2.10142,850299,985142,850Jun 23 09:22 PM
Altman PeterPresident and CEOMar 24Buy2.901,2003,480171,911Mar 26 05:30 PM
Altman PeterPresident and CEOMar 19Buy2.954001,180170,711Mar 23 07:30 AM
Altman PeterPresident and CEOMar 18Buy2.533,3008,349170,311Mar 19 04:02 PM
Altman PeterPresident and CEOMar 17Buy3.66200732167,011Mar 19 04:02 PM
Altman PeterPresident and CEOMar 12Buy3.153,40010,710166,811Mar 16 06:09 AM
Altman PeterPresident and CEODec 31Buy3.674,00014,676163,411Jan 03 03:51 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.